Back to Journals » Drug Design, Development and Therapy » Volume 4
Original Research
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
19,194 | Dovepress* | 17,346+ | 2,085 | 19,431 | |
PubMed Central* | 1,848 | 680 | 2,528 | ||
Totals | 19,194 | 2,765 | 21,959 | ||
*Since 15 November 2010 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
8 | 0 | 0 | 0 | 0 | 8 |
View citations on PubMed Central and Google Scholar